Format

Send to

Choose Destination
Cancer Res. 2017 May 1;77(9):2191-2196. doi: 10.1158/0008-5472.CAN-16-2523. Epub 2017 Apr 20.

Whither Radioimmunotherapy: To Be or Not To Be?

Green DJ1,2, Press OW3,2,4.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. dgreen@fhcrc.org.
2
Department of Medicine, University of Washington, Seattle, Washington.
3
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
4
Department of Bioengineering, University of Washington, Seattle, Washington.

Abstract

Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, particularly B-cell lymphomas. Two "first-generation," directly radiolabeled anti-CD20 antibodies, 131iodine-tositumomab and 90yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized because of a variety of medical, financial, and logistic obstacles. Newer technologies employing multistep "pretargeting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities. The dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficiently compelling to justify human clinical trials and reinvigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, particularly lymphomas. Cancer Res; 77(9); 2191-6. ©2017 AACR.

PMID:
28428282
PMCID:
PMC5413412
DOI:
10.1158/0008-5472.CAN-16-2523
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center